|
| Polyphenol | Study description (patients) | Institution and status |
|
| Curcumin | A Phase II, randomized, double blind, placebo controlled trial for the effectiveness of holistic turmeric supplementation on polyp burden among patients with FAP (40) | Tel Aviv Sourasky Medical Center, Israel; started February 2017 |
|
| Curcumin | Early Phase I, curcumin in combination with 5-FU in chemoresistant metastatic colorectal cancer (14) | Baylor Research Institute, USA; started March 2016 |
|
| Curcumin | Randomized Phase II trial studies in treating patients with FAP (44) | Johns Hopkins University USA; completed in 2017 but results have not been published yet |
|
| Curcumin | Phase I, pharmacokinetic trial of curcuminoids (24) | University of Michigan Cancer Center, USA; completed but no publication |
|
| Curcumin | Phase I, microarray analysis to identify genes that are modified by curcumin that could be used as biomarkers (40) | University of North Carolina, USA; completed but no publication |
|
| EGCG | Phase I, chemopreventive effects in patients with curative resections (50) | The University of Texas Health Science Center at San Antonio, USA; started January 2017 and recruiting |
|
| EGCG | Green tea extracts for the prevention of colorectal adenomas and colorectal cancer (176) | Seoul National University Hospital, South Korea; completed and found favourable outcome for the chemoprevention [153] |
|
| Genistein | Phase I/II, incorporation of genistein in FOLFOX treatment regimen against metastatic CRC (13) | Sofya Pintova, Icahn School of Medicine at Mount Sinai in collaboration with DSM Nutritional Products, Inc., USA; completed January 2017 but result has not been published yet |
|
